Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2013, Article ID 957862, 6 pages
http://dx.doi.org/10.1155/2013/957862
Research Article

Feasibility and Acceptability of a Real-Time Adherence Device among HIV-Positive IDU Patients in China

1Center for Global Health and Development, Boston University School of Public Health, 801 Massachusetts Avenue, Crosstown, 3rd Floor, Boston, MA 02118, USA
2Department of Health Policy and Management, Boston University School of Public Health, Talbot Building, T348W, Boston, MA 02118, USA
3Ditan Hospital, 13 Ditan Park, Andingmen Outer Street, Beijing 100011, China
4FHI 360, Asia-Pacific Regional Office, 19th Floor, Tower 3, Sindhorn Building, 130-132 Wireless Road, Kwaeng Lumpini, Khet Phathumwan, Bangkok 10330, Thailand
5Global Health Strategies, Manila Room, 17th Floor, Ping an International Financial Plaza, Tower B, No. 1-3 Xinyuan South Road, Chaoyang District, Beijing 100022, China
6Guangxi CDC ART Clinic, 18 Jinzhou Road, Nanning, Guangxi 530028, China
7Center for Global Health, Massachusetts General Hospital, 100 Cambridge Street, 15th Floor, Boston, MA 02114, USA

Received 30 March 2013; Accepted 26 June 2013

Academic Editor: Curt Beckwith

Copyright © 2013 Mary Bachman DeSilva et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

We collected data on feasibility and acceptability of a real-time web-linked adherence monitoring container among HIV-positive injection drug users (IDU) in China. “Wisepill” uses wireless technology to track on-time medication dosing. Ten patients on antiretroviral therapy (ART) at the Guangxi CDC HIV clinic in Nanning, China, used Wisepill for one ART medication for one month. We monitored device use and adherence and explored acceptability of the device among patients. Mean adherence was 89.2% (SD 10.6%). Half of the subjects reported a positive overall experience with Wisepill. Seven said that it was inconvenient, supported by comments that it was large and conspicuous. Five worried about disclosure of HIV status due to the device; no disclosures were reported. Twelve signal lapses occurred (5.4% of prescribed doses), of which one was due to technical reasons, nine to behavioral reasons (both intentional and unintentional), and two to unclear reasons. Although the technical components must be monitored carefully, and acceptability to patients presents challenges which warrant further exploration, the Wisepill device has potential for adherence interventions that deliver rapid adherence-support behavioral feedback directly to patients, including IDU. The use of wireless technology appears uniquely promising for providing time-sensitive communication on patient behavior that can be harnessed to maximize the benefits of HIV treatment.